Swedish Orphan Biovitrum AB (publ)

Stockholm Stock Exchange:SOBI.ST

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💉 Vaccines

Location

Sweden

Market Cap

USD 10.01 B

Share Price

USD 29.13

Avg Daily Volume

349,425

Change (1 day)

0.10%

Change (1 year)

10.03%

Change (YTD)

1.65%

Swedish Orphan Biovitrum AB (publ) Long-Term Debt for the year ending December 31, 2024: USD 1.14 B

Swedish Orphan Biovitrum AB (publ) Long-Term Debt is USD 1.14 B for the year ending December 31, 2024, a 0.29% change year over year. Long-term debt is bebt obligations with maturities beyond one year.

Swedish Orphan Biovitrum AB (publ) Long-Term Debt for the year ending December 31, 2023 was USD 1.14 B, a 275.60% change year over year.
Swedish Orphan Biovitrum AB (publ) Long-Term Debt for the year ending December 31, 2022 was USD 302.83 M, a -69.52% change year over year.
Swedish Orphan Biovitrum AB (publ) Long-Term Debt for the year ending December 31, 2021 was USD 993.54 M, a -21.52% change year over year.
Swedish Orphan Biovitrum AB (publ) Long-Term Debt for the year ending December 31, 2020 was USD 1.27 B, a -27.72% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Long-Term Debt	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments

Stockholm Stock Exchange: SOBI.ST

Swedish Orphan Biovitrum AB (publ)

CEO	Dr. Guido Oelkers Ph.D.
IPO Date	Sept. 15, 2006
Location	Sweden
Headquarters	Tomtebodavägen 23A
Employees	1,895
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💉 Vaccines

Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.